Lilly expands research in Singapore with focus on sleep quality
Eli Lilly and Co. plans to set up a $31 million digital health innovation hub in Singapore, expanding its research and development in the city-state.
Eli Lilly and Co.
-
Why Lilly is pouring billions into LEAP
In recent years, the pharmaceutical manufacturer has seen dizzying growth in its pipeline for a wide range of diseases. And modes of drug delivery are becoming increasingly complex.
Read More -
Lilly to invest another $4.5B in Lebanon site for new ‘medicine foundry’
The new funding, for an advanced manufacturing and drug development center, will bring the Indianapolis-based drugmaker’s total investment in the Boone County site to more than $13 billion.
Read More -
Lilly to make $1.8B investment in two Ireland manufacturing facilities
The expansion projects will boost production of medicines for Alzheimer’s disease, diabetes and obesity.
Read More -
How Lilly wooed Massachusetts biotech with flurry of offers
It was a mating dance that lasted more than three years. At the end, Eli Lilly and Co. wound up buying a Massachusetts-based biotech developing treatments for inflammatory bowel disease for $3.2 billion.
Read More
Articles
Lilly CEO Dave Ricks named Watanabe Award winner
Ricks is being recognized for his contributions to Indiana’s life sciences sector and his global impact on health care innovation.
UPDATE: Lilly shares tumble on earnings report that falls short of Wall Street expectations
The Indianapolis-based drugmaker missed expectations on sales of two popular drugs, diabetes treatment Mounjaro and weight-loss treatment Zepbound, which it attributed to inventory decreases in the wholesaler channel.
UK regulator approves Lilly’s new Alzheimer’s drug but government won’t pay for it
Britian’s National Institute for Health and Care Excellence said more evidence was needed to prove Kisunla’s worth. Lilly says a year’s worth of treatment is $32,000.
Amid backlash, FDA changes course over shortage of Lilly weight-loss drugs
The U.S. Food and Drug Administration said it would not take enforcement action—for now—against pharmacies making their own versions of weight-loss drugs based on Eli Lilly’s tirzepatide.
Alzheimer’s patients and their families hear a new word: Progress
Two new drugs—including one from Indianapolis-based Eli Lilly—and better detection methods offer promise for people dealing with the disease.
Lilly weight-loss drug copycat makers sue FDA for taking drugs off shortage list
The plaintiffs allege that the shortage of Lilly’s drugs isn’t actually over, and that the agency’s decision deprives patients of important medicines by restricting compounding.
Eli Lilly’s weight-loss drugs no longer in shortage, FDA says
Lilly has been making the case since August that its tirzepatide-based drugs are now “commercially available,” which the FDA agreed on. But the agency warned that patients and prescribers might still experience “localized supply disruptions.”
Roche has more than five weight-loss companion medicines, CEO says
The the Swiss drugmaker will face off in the obesity area with leaders Novo Nordisk A/S and Indianapolis-based Eli Lilly and Co.
Weight-loss drugs are supposed to be forever … until they run out
Recurrent shortages, shifting insurance coverage, indecision and a lack of guidance about side effects and dosing have led to challenges for some patients prescribed Mounjaro, Ozempic, Zepbound or Wegovy.
Lilly seeks court ruling that could mean big money for new weight-loss drug
The Indianapolis-based drugmaker filed a suit in federal court this month, challenging the U.S. Food and Drug Administration’s ruling that the company’s experimental obesity treatment not a biological product.
Eli Lilly requests records of people who took copies of its weight-loss drug
The letter is the latest sign that the battle between the brand-name drug manufacturers and the companies that make and sell the compounded versions has intensified.
Lilly names new chief financial officer
Lucas Montarce, who has been with Lilly since 2001 and most recently served as president for its Spain, Portugal and Greece operations, is now the company’s CFO and executive vice president.
Eli Lilly ramps up fight against imitation weight-loss drugs
Lilly and rival Novo Nordisk have been battling the emerging industry making copies of their top-selling diabetes and weight-loss drugs, a situation without modern precedent.
Olympians Biles, Thomas continue Indy trip with visit to Lilly
After taking in the Indiana Fever’s victory on Wednesday, Simone Biles and Gabby Thomas discussed teamwork on Thursday with thousands of employees for Team USA sponsor Eli Lilly and Co.
Lilly now selling vials of blockbuster Zepbound at 50% discount
Lilly said its new option will help millions of adults with obesity access the medicine they need, including those not eligible for the Zepbound savings card program, those without employer coverage, and those who need to self-pay outside of insurance.
Study: Lilly’s Zepbound cut risk of diabetes by 94% in obese people
The longest continuous study of Indianapolis-based Lilly’s drug Zepbound to date included more than 1,000 patients.
Lilly opens new 12-story, $700M R&D center in Boston
Lilly is moving about 200 scientists and researchers who had worked in nearby Cambridge, Massachusetts, to the new center, and plans to add about 300 employees.
Purdue, Lilly establish medical-focused research center
The Eli Lilly and Co. and Purdue University Research Alliance Center involves more than 50 researchers and 65 graduate students.
Eli Lilly taps blue-chip bond market to fund Morphic acquisition
Lilly is buying Morphic for $3.2 billion to gain experimental therapies for inflammatory bowel disease and other chronic illnesses.